Spyre Therapeutics CEO Cameron Turtle sells $1.38m in SYRE stock

Cameron Turtle, CEO and Director of Spyre Therapeutics, sold 14,000 shares of the company's stock on October 1, 2026, resulting in a sale value of approximately $1.38 million. The shares were sold at prices ranging between $89.14 and $93.91, following a trading plan adopted on June 20, 2025. Despite the stock surging 487% over the past year, analysts believe the shares are currently overvalued.

Mr. Turtle now owns 537,540 shares, including some that vest monthly through November 2026. The company remains unprofitable this year, with analysts predicting continued unprofitability. Recent news includes the Phase II SKYWAY-RA program results, showing significant efficacy improvement over placebo in rheumatoid arthritis patients, although it did not meet Spyre's development threshold.

This led to a decline in the stock price, but ratings from Stifel, Guggenheim, JPMorgan, and Baird remain positive, with varying price targets.